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Abstract
Purpose: The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome.
As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional
prognostic information.
Patients and Methods: We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and
analysed for TP53 mutations and 17p loss. The majority of cases were profiled by copy number (n = 32) and gene expression
(n = 36) arrays. TP53 mutational status was correlated with patient event-free and overall survival, genomic copy number
instability and gene expression profiling.
Results: From the 40 cases, 22 (55%) had TP53 mutations (2 detected only after deep-sequencing), 20 of which also had 17p
loss (91%); 18 (45%) cases had no detectable mutation but three had 17p loss. Tumours with TP53 mutations and/or 17p
loss (n = 25) had an increased risk of recurrence as a first event (p = 0.03, hazard ratio (HR), 3.89; 95% confidence interval (CI),
1.26–16.0) and death (p = 0.04, HR, 4.95; 95% CI, 1.36–31.7) compared to tumours lacking TP53 abnormalities. DAWT carrying
TP53 mutations showed increased copy number alterations compared to those with wild-type, suggesting a more unstable
genome (p = 0.03). These tumours showed deregulation of genes associated with cell cycle and DNA repair biological
processes.
Conclusion: This study provides evidence that TP53 mutational analysis improves risk stratification in DAWT. This requires
validation in an independent cohort before clinical use as a biomarker.
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Introduction
Wilms tumour (WT) or nephroblastoma, the most frequent
renal tumour of childhood, affects around 1 in 10,000 children
before the age of 15 years. Most patients with WT in the Western
world are treated within prospective clinical trials conducted by
either the International Society of Paediatric Oncology - Renal
Tumor Study Group (SIOP-RTSG, Europe) or the Children’s
Oncology Group (COG, North America) that each report long-
term survival rates of over 85% [1–8]. However, a substantial
minority (,25%) respond poorly or relapse with current therapies
and approximately 50% of these children will succumb to their
tumour despite intensive re-treatment [9,10].
Risk stratification is largely based on tumour stage and histology
which is key to improving clinical management; 4–10% of WT
display anaplasia, which is defined morphologically by the
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presence of cells with at least threefold nuclear enlargement,
hyperchromasia and abnormal mitotic figures [11]. A further
distinction is made between focal (FA) and diffuse (DA) anaplasia,
based on the topographic distribution of anaplastic elements
within the tumour [12]. Presence of DA is the most important
adverse prognostic indicator in pre-treated (SIOP) and in
chemotherapy-naı¨ve tumours (COG) and patients are assigned
to more intensive treatment [13,14].
TP53 mutations are only found in the anaplastic areas of WT
[15], suggesting an association between TP53 and anaplastic cells.
Only small numbers of cases of DAWT have been analysed for
TP53 mutations, usually as a subgroup of a larger dataset of WT,
reflecting the rarity of this histological type. Four studies have
clearly analysed 14 DAWT, 12 (86%) displayed mutations in
TP53 [15–18]. TP53 mutations were also evaluated in anaplastic
WT (AWT) without further classification [19]. Although TP53
mutation seems to be predictive of response to treatment and
patient survival in several cancers, studies that used immunohis-
tochemistry to investigate p53 prognostic value yielded inconsis-
tent results [20], leading to the conclusion that this technique
alone is not suitable for assessing TP53 mutational status.
Immunostaining for p53 is positive in ,76% of anaplastic WT
and ,8% of favourable histology WT - those with ‘nuclear unrest’
which harbour only some of the morphological criteria to be
considered anaplastic [21,22]. In pre-treated patients, p53
positivity was associated to high risk cases that relapsed [23].
Previously, we showed 17p loss in a significant proportion of
AWT [24]. Since only small cohorts of DAWT were previously
evaluated for TP53 mutation and its clinical implications could
therefore not be rigorously assessed, we brought together the
largest cohort of anaplastic WT analysed to date to investigate
whether the generally accepted frequency of TP53 mutations is
correct, and to determine the relationship between TP53 status
and patient outcome.
Methods
Patients and samples
Forty patients with unilateral DAWT were included in this
analysis. The inclusion criteria were: Wilms tumour with diffuse
anaplasia confirmed by central pathology review according to
standard international criteria [12] and presence of anaplastic
features in the frozen tumour specimen used to extract DNA.
Thirty-two cases came from the COG tumour bank and eight
from the UK Children’s Cancer and Leukaemia tumour bank. All
32 patients from COG were enrolled on the National Wilms
Tumor Study-5 protocol (08/1995 to 05/2002) [13] and eight
patients were treated in the SIOP WT 2001 trial (02/2002 to 12/
2011). All patients were treated according to the high risk arm of
their respective trials (Tables S1 and S2).
The frozen tumour samples were taken from a larger cohort of
51 DAWT similarly subject to central pathology review. However
11 tumours were excluded from analyses either because they
lacked evidence of anaplasia in the frozen specimen (n = 6) or it
was not possible to clearly categorise the haematoxylin-eosin
section of the frozen specimen (n = 5).
All samples were obtained from patients whose parent or legal
guardian had provided written informed consent for research use
(or for older patients, the patient themselves had provided written
consent or assent), in accordance with national regulations. Ethical
approval for the study was given by East Midlands - Derby
Research Ethics Committee (National Research Ethics Service
(NRES) in the United Kingdom) with reference approval number
MREC/01/4/086 given on 17th January 2002.
Sequencing and analysis of TP53
Genomic DNA was extracted using proteinase K digestion
followed by phenol/chloroform extraction as described by
manufacture’s recommendations. Primer sequences, product
lengths and PCR conditions for the 11 exons of TP53 were
retrieved from the IARC TP53 website [20]. Sanger sequencing
was performed using the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) according to the manufac-
turer’s protocol using an ABI PRISM 3130 Genetic Analyzer
(Applied Biosystems). Sequences were analysed using Mutation
Surveyor software v3.20 (SoftGenetics).
Samples negative for TP53 mutations by Sanger sequencing
were deep-sequenced to detect mutations present in a minority cell
population. Indexed libraries of the PCR products were prepared
using the Illumina Nextera XT kit with supplied protocol and
sequenced using an Illumina MiSeq instrument, generating
26150 bp reads with a mean coverage of 162x. Only sequences
that passed quality control were analysed further. All sequence
alterations were reviewed in the Integrative Genomics Viewer
(IGV) version 2.3 [25] and classified as missense, nonsense
frameshift, in frame duplication, in frame deletion or splicing
mutations by ANNOVAR [26].
Multiplex Ligation-dependent Probe Amplification
(MLPA) analysis
Chromosome 17p copy number, where TP53 is located, was
assessed by a MLPA assay (P380-X2 custom probemix, MRC-
Holland b.v.) according to the manufacturer’s protocol (http://
www.mrc-holland.com) using 100 ng of DNA (Qubit) with A260/
A230 $1 (Nanodrop) and containing $10 mM Tris-HCl pH 8.2
was used. Data normalisation and analysis was performed with
Genemarker v1.85 (Softgenetics).
Analyses of Copy Number and Gene Expression using
Microarrays
To infer genomic instability and to confirm 17p loss identified
by MLPA, we used genomic copy number BAC arrays from our
previously reported data set [24], which has an overlap of 32
patients with the 40 patients from this study. In summary, cases
were co-hybridized against unmatched, unrelated pooled normal
DNA on the Breakthrough Breast Cancer Research Centre 32k
BAC tiling path CGH array. Copy number alterations were
calculated based on circular binary segmentation [27,28] followed
by merging of adjacent segments that did not differ significantly in
copy number [29], as implemented in the Bioconductor packages
DNAcopy and aCGH (http://www.bioconductor.org). Genomic
instability was defined in the case of an alternating status in the
level of copy number alterations (CNA) [30,31] using three
parameters: 1. More than two contiguous BAC probes with the
same copy number, 2. Size range between 1 Kb and 100 Mb to
exclude non-focal CNA and 3. Segmentation predicted #0.1 for
loss and $0.1 for gain.
From the same study [24], we retrieved gene expression profiles
of 36 cases that also overlap with the 40 patients from this study,
and identified differences in gene expression between samples with
wild-type and mutated TP53. In summary, tumour and reference
cDNA (Universal Human Reference cDNA (Stratagene, La Jolla,
CA) were co-hybridized to the Breakthrough Breast Cancer
Research Centre 17k 2.1.2 cDNA microarray (ArrayExpress
accession number A-MEXP-259). Data are available at GEO
(GSE609400).
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Statistical analyses
Event-free survival (EFS) was defined to be the time from
diagnosis to disease recurrence or other disease related event
(including death as a first event from any cause), both clinically
identified. Overall survival (OS) analysis included cancer-related
deaths, one case where death resulted from infection and one case
from toxicity (both had suffered relapse as a first event); the
survival interval was calculated relative to the date of diagnosis.
Estimates of time-to-event distributions were calculated using the
Kaplan-Meier method and differences compared using the log-
rank test. Estimates of the relative risk of events between patient
subsets were estimated using the Cox regression model. Patients
were right censored due to end of study or loss to follow up.
These analyses were performed using IBM SPSS version 21 for
Windows and SAS version 9.3. Two-tailed student’s t-test
assuming unequal variance (given by Levene’s test) was used to
compare the quantity of copy number alterations between two
groups: with wild-type or mutant TP53.
All results were considered significant when p-values were less
than 0.05.
Expression analyses were performed using BRB-ArrayTools
developed by Dr. Richard Simon and the BRB-ArrayTools
Development Team. The BRB-ArrayTools was used to identify
differentially expressed genes between wild-type and mutated
TP53, and for gene ontology analyses. After a LOWESS
normalization procedure, the class comparison tool uses a Two-
sample T-test to find discriminating genes and to confirm their
statistical significance p#0.01. We compared tumours with
mutTP53 versus wtTP53. Biological processes were considered
over-represented when 1) at least five genes were classified in that
process and 2) an observed vs. expected’ ratio of .2-fold was
observed.
Results
Characterization of TP53 in the tumours
All samples were screened for TP53 mutations in exons 1 to 11,
including intron-exon boundaries, with reference to the published
wild type sequence (Chr 17 NC_000017.9, Table S3). Distribu-
tion of cases with respect to TP53 status is displayed in Figure 1.
Due to the rarity of DAWT, samples were pooled from two
major tumour banks (NWTSG-5 and UK SIOP 2001). There
were 51 patients with DA confirmed by central review from which
we used 40 for further analyses. For the 40 patients, the median
age at diagnosis was 4.6 years (1.42 to 9.17 years, which is older
than reported for non-anaplastic WT [32]. Only one patient was
aged less than 2 years at diagnosis and did not relapse. The stage
distribution was 11 stage I, (27.5%); 8 stage II (20%), 16 stage III
(40%); 5 stage IV (12.5%).
Of the 40 cases, 20 (50%) had at least one TP53 mutation
detected by Sanger sequencing; one case had two mutations
(Table 1). In two further cases, TP53 mutations were only
detected by deep sequencing (162-fold). The pathology review
noted that DA within the tumour was in the middle of a larger
proportion of fat and necrotic cells in one case but the other had a
classical presentation of DA. One case (1136) had mutation
already described in AWT [16] (Table 1).
The other 18 DAWT samples did not have mutations despite
clear morphological evidence of anaplasia in the frozen section. All
mutations are described in the IARC TP53 Database (http://
www-p53.iarc.fr/) [20]. Loss of TP53 was identified by MLPA in
an additional 3 cases without TP53 mutation. In total, 20 out of
25 cases (80%) had TP53 mutation and/or 17p loss.
Several additional alterations were previously reported to be
normal variations in the population at frequencies of 0.5–60%
(source: dbSNP) and assumed to lack functional consequences
(Table 2). These variants may have an unknown significance for
the patients with AWT, particularly in those three cases with only
17p loss. These were not considered for outcome analysis.
Mutations in TP53 effectively risk stratify patients with
DAWT
The two cohorts (COG and SIOP) were similar in terms of their
clinicopathologic characteristics and overall survival (Tables S1
and S2). Whilst this does not preclude that a larger cohort might
display different characteristics, outcomes were similar in both
trials. Among 32 patients treated in the COG trial, 13 (41%)
relapsed and 11 (34%) died, whereas among 8 patients treated in
the SIOP trial, 4 relapsed and died (50%). Typically, patients with
DAWT relapse within 2 years and only one patient had a follow-
up shorter than 5 years (2.39 years); the median follow-up period
of patients still alive (n = 25) was 5.92 years.
For the 17 patients (out of 40) that experienced an event,
median time from initial diagnosis to tumour recurrence was 0.75
years (range 0.34–1.61 years) and to death was 1.27 years (range
0.5–2.25 years). We defined mutated cases (mutTP53) as those 25
with damaging aberrations identified by either sequencing
methodology, Sanger (20 cases) or deep-sequencing (2 cases),
and/or 17p loss identified by MLPA (23 cases) with an overlap of
21 cases between sequence mutations and locus loss. The other 15
cases were considered wild-type TP53 (wtTP53) cases.
The 15 patients with wtTP53 had statistically significantly
better EFS than the 25 patients with mutTP53 (p = 0.02,
Figure 2A). Five-year EFS estimates were 80% for patient with
wtTP53 and 44% for patients with mutTP53. The estimated
hazard ratio (HR) for failure comparing mutTP53 to wtTP53 was
3.89 (95% profile likelihood confidence interval (CI): 1.26, 16.9).
The results were similar for overall survival. Patients with
wtTP53 had statistically significantly better OS than the patients
with mutTP53 (p = 0.02, Figure 2B). Five-year OS estimates
were 86% for patients with wtTP53, compared to 48% for
patients with mutTP53. The estimated HR for death comparing
mutTP53 to wtTP53 was 4.95 (95% profile likelihood CI: 1.36,
31.7). All but one of the 15 deaths was due to tumour progression
or relapse. Only a single patient with initial stage I DAWT was
known to be alive after relapse (Table S2, case 1136). From the 7
stage I/II patients wild type for TP53 only one relapsed, whilst 6
out of 12 stages I/II patients with mutated TP53 relapsed.
Unfortunately, the number of patients used in this study doesn’t
allow us to draw conclusions regarding the association between
stage and relapse or TP53 mutation.
Mutations in TP53 are associated with genomic instability
To determine if TP53 mutation was associated with the
genomic instability described previously in tumours with anapla-
sia, copy number alterations (CNAs) were analysed by aCGH in
32 samples. While cases with wtTP53 (n = 13) had an average of
26.6 (standard deviation (SD) 618.4) CNAs, cases with mutated
TP53 (n = 19) had a significantly higher average of 44.7 (SD
626.1) CNAs (Table S2). The mean difference was 18.1 (95% CI
of difference, 2.0 to 34.2) between groups (p = 0.03, Student’s
t-test).
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Cell cycle pathways are altered in DAWT with TP53
mutations
Gene expression profile was compared between 21 DAWT
cases with mutTP53 and 15 DAWT cases with wtTP53. This
analysis revealed 93 differentially expressed genes (p#0.01, t-test,
Table S4), with over-representation of genes that participate in
cell cycle: AURKA, RNF8, BRCA2, RPS27L, NOL10, RRM2,
ORC5, CCNO, HUS1, CDKN1A, FAM83D, PSMC2, NCAPH,
PKP4, SUPT5H, USP3, FGFR10P, BUB1, TP53, MLF1,
CCNB2, PSMB2, CDC20 and SPC25; and DNA repair
processes: RNF8, EGR1, RPS27L, CCNO, HUS1, USP3,
TP53, CDKN1A, PSMB2, PSMC2, CCNB2, MORF4L2,
TNSF11 and ZMAT3 (Table S5). As expected, TP53 was
overexpressed in the wild-type group of samples.
Discussion
This study aimed to identify how frequently TP53 mutation
underlies DAWT and whether its presence adds additional
prognostic information. In this largest set yet described of DAWT,
where molecular analysis was confined to DNA extracted from
tissue with confirmed anaplastic changes, we found an overall
mutation frequency of only 55% (22/40), lower than previously
reported [15–18], while 17p loss was observed in 58% (23/40) of
the cases, with 20 cases showing both TP53 mutation and 17p
loss. Interestingly, from 20 tumours that were TP53 wild-type by
Sanger sequencing, mutations were found in further 2 cases by
deep sequencing (162-fold). Hence, only 63% (25/40) of definite
DAWT had detectable TP53 abnormality even when assessed by
the most sensitive technology.
A significant association between poor event free and overall
survival and TP53 mutation suggests that it is a potential adverse
prognostic factor in addition to anaplastic morphology. The 5-
years EFS and OS of patients with DAWT with wtTP53 were
80% and 86%, respectively, not too dissimilar to the reported EFS
and OS of patients with favourable histology tumours treated in
the same clinical trials [32–34]. However these patients receive
more intensive treatment, including doxorubicin, with a predict-
able risk of long term health problems including cardiac failure
and second cancer [35,36]. It remains to be addressed by future
studies and clinical trials if patients with DAWT with and without
TP53 mutations can be classified into different risk categories and
have different treatment strategies.
Ten of the mutations we described have been reported in Li-
Fraumeni families (Table 1), an autosomal dominant syndrome
associated with germline TP53 mutations, characterised by a high
incidence of a range of tumours, with WT not being one of the
cardinal tumours included in the diagnostic criteria. Some families
harbouring TP53 mutations display a higher WT incidence; five
out of six Li-Fraumeni families that developed WT had mutations
affecting splicing of TP53 [37], suggesting an association between
risk of these patients to develop WT and the type of TP53
mutation. Such mutations account for only 4% of all reported
Figure 1. Consort diagram showing the 40 cases of diffuse anaplastic Wilms tumour used for the survival analysis by TP53mutation
and/or 17p loss.
doi:10.1371/journal.pone.0109924.g001
TP53 Status Is a Powerful Prognostic Marker in DAWT
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e109924
germline mutations [38]. Constitutional DNA was not available to
exclude the possibility of these mutations being germline.
In the specific biological context of Li-Fraumeni syndrome and
medulloblastoma, TP53 mutations have been associated with
chromothripisis, an event characterized by massive genomic
Table 1. Cases of diffuse anaplastic WT with TP53 mutations.
Sample Trial
Copy number
at TP53 locus Exon Mutation (annotation in Hg19)
Frameshift deletion
1149 COG Loss 10 g.7573999-7574008het_delTGTTCCGAGA
3036 COG Loss 10 g.7574000-7574006delTTCCGAG
3048 COG Loss 10 g.7574013-7574013het_delC
Frameshift insertion
3477 SIOP Loss 11 g.7572933-7572933dupA
Nonframeshift deletion
2557 SIOP Loss 5 g.7578447-7578447dupCATCTACAAGCAGTCACAGCACATGAC
1144 COG Loss 6 g.7578275-7578277delCTC
1133 COG Loss 10 g.7574026-7574026dupGGCGTG
Nonsynonymous SNV
3044 COG Loss 5 g.7578406-7578406G.GA¥
3047 COG Loss 5 g.7578457-7578457G.GC
3052 COG Loss 5 g.7578526-7578526G.GT
3056 COG Loss 5 g.7578413-7578413G.A¥
3143 SIOP Loss 5 g.7578394-7578394A.C¥
1142 COG Loss 8 g.7577120-7577120G.GA¥
1706 SIOP Loss 8 g.7577120-7577120G.GA¥
2967 SIOP Loss 8 g.7577129-7577129T.TG
1134{ COG Loss 8 g.7577118-7577118G.GT¥
1134{ COG Loss 8 g.7577095-7577095C.CA
1145* COG Normal 8 g.7577124C.T¥
3041 COG Loss intronic g.7578298-7578308delCCTCACTGATT
1135 COG Normal intronic g.7578296-7578305het_delTCACTGATTG
9533 SIOP Unknown 10 g.7574002C.G¥
Stopgain SNV
4718 SIOP Loss 6 g.7578212-7578212C.CT¥
1136 COG Loss 10 g.7574003-7574003C.T¥
3145* SIOP Loss 6 g.7578263-7578263G.A¥
SNV: Single Nucleotide Variation.
{: Case that had two mutations together with TP53 loss.
*Cases identified by deep-sequencing.
¥Mutations found in Li Fraumeni patients (IARC TP53 Database, R17).
doi:10.1371/journal.pone.0109924.t001
Table 2. Variants with unknown function in cases with 17p loss.
Cases SNP location SNP dbSNP MAF
Synonymous SNV
3043, 3061, 3864 Exon 4 g.7579472-7579472C.G, NM_001126118:c.C98G:p.P33R rs1042522 0.3979
Silent mutations
3043, 3060, 3061 Exon 11, UTR 3’ g.7572890-7572890A.T rs1042526 not available
3043, 3061 Exon 2, UTR 5’ g.7579801-7579801C.G rs1642785 0.3636
3043, 3060, 3061 intronic g.7579644-7579659del16 not available
MAF: minor allele frequency (source: dbSNP).
doi:10.1371/journal.pone.0109924.t002
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rearrangements, causing genomic instability [30], which may be
an important evolutionary driver of metastatic ability or chemo-
therapy treatment resistance [39]. Similar events have been
observed in chronic lymphocytic leukaemia [40] and osteosarco-
mas [41]. We also found that the DAWT with mutated TP53 had
more CNAs than the DAWT with wild-type alleles, indicating that
the cells are in a state of genomic instability, likely to be a
consequence of the mutated TP53. Whether increase in genomic
instability is a function of time remains to be addressed.
Hence, unsurprisingly, cell cycle and DNA repair processes
were over-represented among the differentially expressed genes.
As a cell cycle inhibitory transcription factor, TP53 regulates
genes that enforce its growth inhibitory functions in response to
oncogenic or damage-induced stress [42]. RPS27L and
CDKN1A, known TP53 targets, are down-regulated in tumours
without wild-type TP53, a similar finding to a study that evaluated
TP53 targets across ten cancer types [43]. Together with TP53,
CASP8, CDKN1A, ZMAT3, RRM2 and CCNB2 also belong to
the p53 signalling pathway (KEGG), which perturbation is
considered a hallmark of cancer [44]. Among these, only CASP8
has been described in WT. CASP8, down-regulated in DAWT
with mutated TP53, is a pro-apoptotic factor expressed in
favourable histology WT, with no correlation to stage of disease
or risk for tumour recurrence [45].
The genes representative of the DNA repair pathway found by
this study have not been evaluated in WT. Previous studies
reported the lack of defects in the DNA mismatch repair system
mainly in favourable histology WT based on the pattern of protein
expression of MLH1, PMS2, MSH2 and MSH6 [46,47] and
absence of microsatellite instability [47]. Further work will be
necessary to clarify which genes and repair pathways are activated
in the mutated TP53 DAWT and at which extension they are
important for the other WT subtypes. Analysis of prognostic
factors within the histological subgroup of DAWT is challenging,
due to its extreme rarity. Less than 10% of Wilms tumour are
classified as anaplastic, either focal or diffuse [12–14]. Therefore,
to obtain a reliable estimate of the frequency of mutated TP53 in
DAWT, we made several efforts: 1) Samples were combined
through a collaboration between UK and North American clinical
trials. 2) In addition to the rigorous central pathology review
process of each group, the frozen samples used for DNA extraction
were again reviewed to ensure the presence of anaplasia in the
specimen, since an association between the visible anaplastic area
and TP53 mutation is described [15]. 3) Samples that were
negative for mutation by conventional sequencing were re-
sequenced using a high-coverage methodology (next-generation
sequencing). Altogether, these patients and samples were very
carefully reanalysed concerning all aspects of their disease and
morphology. Such attention to detail regarding sample selection
for mutational analysis will, of course, be required where such an
assay may be applied in the real life clinical situation in the future.
TP53 mutational status appears to be an additional indicator of
prognosis as it discriminates two classes of anaplastic WT with
different outcomes. The value of TP53 mutation analysis in the
diagnostic work-up of patients with DAWT should now be tested
in an independent cohort in order to answer the important
question of whether DAWT without TP53 mutations could be a
candidate for reduction in therapy. However, it is possible that the
relatively good outcomes were the result of the intensive multi-
agent therapy used in modern treatment protocols. As we are
approaching the limit of tolerability of classical chemotherapy
treatment for these patients, it is clear that novel therapeutic
strategies are necessary to cure patients with DAWT and
mutTP53.
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(dashed line) versus mutTP53 (solid line). Numbers at risk are plot every year. HR: hazard ratio, CI: confidence interval.
doi:10.1371/journal.pone.0109924.g002
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